Ignite Creation Date:
2025-12-25 @ 3:24 AM
Ignite Modification Date:
2025-12-26 @ 2:04 AM
Study NCT ID:
NCT01281605
Status:
COMPLETED
Last Update Posted:
2018-08-20
First Post:
2011-01-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 181}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-03', 'completionDateStruct': {'date': '2016-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-08-16', 'studyFirstSubmitDate': '2011-01-20', 'studyFirstSubmitQcDate': '2011-01-20', 'lastUpdatePostDateStruct': {'date': '2018-08-20', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2011-01-24', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To compare the change in HbA1c between two study groups at Week 24.', 'timeFrame': '24 weeks', 'description': 'compare the change in HbA1c between two study groups after 24 weeks treatment.'}], 'secondaryOutcomes': [{'measure': 'To compare the change in HbA1C between two study groups at Week 12.', 'timeFrame': '12 weeks', 'description': 'compare the change in HbA1C between two study groups after 12 of treatment.'}, {'measure': 'To compare the proportion of patients achieving HbA1C <7% at Week 24', 'timeFrame': '24 weeks', 'description': 'compare the proportion of patients achieving HbA1C \\<7% after 24 weeks treatment'}, {'measure': 'To compare the changes in fasting plasma glucose (FPG) at Week 12 and 24.', 'timeFrame': '24 weeks', 'description': 'compare the changes in fasting plasma glucose (FPG) after 12 and 24 treatment.'}, {'measure': 'To compare the change in body weight at each visit', 'timeFrame': '24 weeks', 'description': 'compare the change in body weight at each visit'}, {'measure': 'To evaluate the incidence of adverse events.', 'timeFrame': '24 weeks', 'description': 'evaluate the incidence of adverse events including hypoglycemia and any other adverse event.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Type 2 diabetes', 'Basal insulin', 'Insulin detemir', 'Insulin titration algorithm'], 'conditions': ['Type 2 Diabetes']}, 'descriptionModule': {'briefSummary': 'This study compared the effectiveness and safety of two treatment algorithms for insulin detemir initiation and titration: active titration algorithm (performed by investigator weekly) versus usual titration algorithm (performed by study subjects weekly) in patients with type 2 diabetes poorly controlled by OADs.', 'detailedDescription': 'This is a 24-week, prospective, open-label, randomized, parallel-group study conducted in approximately 200 patients with type 2 diabetes in the Taiwan. The effectiveness of insulin detemir will be assessed at baseline and at 12 and 24 weeks after initiation of study prescription. The safety will be followed during the 24-week study period.\n\nInclusion criteria:\n\nPatients must meet all of the following criteria:\n\n1. Men and women with type 2 diabetes.\n2. 20 years of age.\n3. Patients who have received stable doses of any OADs for at least 10 weeks prior to the screening visit.\n4. Patients with inadequate glycemic control (HbA1C \\>=7% and \\< 11%).\n5. Patients who are willing and able to cooperate with study and give signed informed consent.\n\nAfter enrollment, eligible patients will be randomized in a 1:1 ratio to one of the following titration algorithms:\n\n* Active titration algorithm: contact with investigator by telephone weekly.\n* Usual titration algorithm: contact with investigator only at routine study visit.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nPatients must meet all of the following criteria:\n\n1. Men and women with type 2 diabetes.\n2. 20 years of age.\n3. Patients who have received stable doses of any OADs for at least 10 weeks prior to the screening visit.\n4. Patients with inadequate glycemic control (HbA1C \\>=7% and \\< 11%).\n5. Patients who are willing and able to cooperate with study and give signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with type 1 diabetes.\n2. Renal dialysis patients.\n3. History of hypoglycemia unawareness.\n4. Patients who had received any insulin for more than 2 weeks or who have received insulin treatment within 4 weeks prior to screening visit.\n5. Patients who have received any investigational products (drug and device) within 4 weeks prior to screening visit.\n6. Patients hypersensitive with insulin detemir or its excipients.\n7. Patients who are currently pregnant/lactating,or who are preparing for pregnancy or lactation.'}, 'identificationModule': {'nctId': 'NCT01281605', 'briefTitle': 'Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes', 'organization': {'class': 'OTHER', 'fullName': 'Mackay Memorial Hospital'}, 'officialTitle': 'Comparison of Two Titration Programs of Adding Insulin Detemir to Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes Patients', 'orgStudyIdInfo': {'id': '10M MHIS112'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Active titration algorithm', 'description': 'titrate insulin dose by contacting with investigator by telephone weekly.', 'interventionNames': ['Behavioral: Active titration algorithm']}, {'type': 'EXPERIMENTAL', 'label': 'Usual titration algorithm', 'description': 'contact with investigator only at routine study visit.', 'interventionNames': ['Behavioral: Usual titration algorithm']}], 'interventions': [{'name': 'Active titration algorithm', 'type': 'BEHAVIORAL', 'otherNames': ['Insulin detemir active titration algorithm'], 'description': 'Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(\\<110mg/dl).', 'armGroupLabels': ['Active titration algorithm']}, {'name': 'Usual titration algorithm', 'type': 'BEHAVIORAL', 'otherNames': ['Insulin detemir usual titration algorithm'], 'description': 'All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG\\>=110mg/dL, and by 4 IU/day if the FPG\\>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG \\< 70 mg/dL.', 'armGroupLabels': ['Usual titration algorithm']}]}, 'contactsLocationsModule': {'locations': [{'zip': '30067', 'city': 'Hsinchu', 'country': 'Taiwan', 'facility': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Hsinchu branch', 'geoPoint': {'lat': 24.80361, 'lon': 120.96861}}, {'zip': '10449', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Mackay Memorial Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '95054', 'city': 'Taitung', 'country': 'Taiwan', 'facility': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Taitung branch', 'geoPoint': {'lat': 22.75991, 'lon': 121.14457}}], 'overallOfficials': [{'name': 'Sung-Chen Liu, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital'}, {'name': 'Hui-Fang Chang, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Hsinchu branch'}, {'name': 'Ke-Yan Wu, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Taitung branch'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mackay Memorial Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Division of Endocrinology and Metabolism, Department of Internal Medicine', 'investigatorFullName': 'Sung-Chen Liu', 'investigatorAffiliation': 'Mackay Memorial Hospital'}}}}